FY2024 Earnings Estimate for uniQure Issued By HC Wainwright

uniQure (NASDAQ:QURE) – Equities research analysts at HC Wainwright increased their FY2024 earnings per share estimates for shares of uniQure in a research note issued on Wednesday, November 6th. HC Wainwright analyst P. Trucchio now anticipates that the biotechnology company will post earnings of ($4.16) per share for the year, up from their prior forecast of ($4.84). HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for uniQure’s current full-year earnings is ($4.10) per share. HC Wainwright also issued estimates for uniQure’s Q4 2024 earnings at ($0.74) EPS, Q1 2025 earnings at ($0.62) EPS, Q2 2025 earnings at ($0.64) EPS, Q3 2025 earnings at ($0.66) EPS, Q4 2025 earnings at ($0.77) EPS, FY2025 earnings at ($2.69) EPS, FY2026 earnings at ($2.50) EPS, FY2027 earnings at ($1.20) EPS and FY2028 earnings at $1.40 EPS.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. The business had revenue of $2.29 million during the quarter, compared to the consensus estimate of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%.

A number of other equities research analysts also recently weighed in on QURE. The Goldman Sachs Group lowered their target price on uniQure from $10.00 to $9.00 and set a “neutral” rating for the company in a report on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $28.00 price objective on shares of uniQure in a research note on Wednesday. StockNews.com raised uniQure to a “sell” rating in a research note on Thursday, October 17th. Royal Bank of Canada decreased their price objective on uniQure from $16.00 to $14.00 and set an “outperform” rating for the company in a report on Wednesday. Finally, Raymond James reiterated an “outperform” rating and issued a $20.00 target price on shares of uniQure in a report on Thursday, October 10th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $17.00.

uniQure Stock Up 4.8 %

Shares of NASDAQ QURE opened at $7.79 on Friday. uniQure has a 52-week low of $3.73 and a 52-week high of $11.35. The company’s 50 day moving average price is $5.77 and its 200-day moving average price is $5.82. The company has a market capitalization of $379.68 million, a P/E ratio of -1.57 and a beta of 0.90. The company has a debt-to-equity ratio of 0.92, a quick ratio of 7.36 and a current ratio of 6.51.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Personalized Indexing Management LLC raised its stake in shares of uniQure by 21.0% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 2,306 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of uniQure by 57.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 3,663 shares during the period. American Century Companies Inc. increased its position in shares of uniQure by 14.6% during the second quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company’s stock valued at $303,000 after buying an additional 8,642 shares during the period. Atria Investments Inc bought a new position in uniQure in the third quarter worth about $53,000. Finally, Clear Harbor Asset Management LLC boosted its position in shares of uniQure by 35.2% during the second quarter. Clear Harbor Asset Management LLC now owns 48,000 shares of the biotechnology company’s stock valued at $215,000 after purchasing an additional 12,500 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.